We observed that TRIM56 was successfully overexpressed and that Trim56-HepOE mice showed protection against NAFLD evidenced by decreased liver weight, hepatic TG levels, and hepatic lipid accumulation (Figure 3, K–N). Here, TRIM56 is linked to metabolic dysfunction-associated steatotic liver disease.